Company intelligence / Profile preview
BPGbio
Framingham, Massachusetts, United Statesbpgbio.com ↗
- Ownership
- Private
- Employees
- ~250
- Development stage
- Other
01
Overview
BPGbio’s AI-powered NAi Interrogative Biology® platform has led to the discovery of five Phase II/III-ready drug candidates and over a hundred novel targets and biomarkers. The company reports successful clinical trial outcomes driven by its multiomics data integration approach. Its pipeline includes advanced programs in oncology, rare diseases, and neurology.
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Targeted protein degradation (E2 Platform)Multiomics-driven drug discoverySmall molecules and biologics (inferred from platform focus)
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Not explicitly listed; collaborations with Oak Ridge National Laboratory for supercomputing resources are noted.
Beyond the preview
Go deeper on BPGbio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPGbio.